Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma

Br J Ophthalmol. 2023 Mar;107(3):320-323. doi: 10.1136/bjophthalmol-2021-319417. Epub 2021 Oct 8.

Abstract

Purpose: To report on the outcomes of immunotherapy in patients with locally advanced periorbital squamous cell carcinoma.

Methods: We performed a retrospective chart review of seven consecutive patients with locally advanced periorbital cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy. Treatments and therapeutic outcomes were reviewed.

Results: Of the seven patients, six were treated with cemiplimab, and one was treated with pembrolizumab. Five patients were treated with immunotherapy as neoadjuvant therapy before planned surgical resection; two patients received immunotherapy for treatment of advanced recurrent lesions deemed unresectable following multiple previous excisions and radiation therapy. In all seven patients, measurable clinical and/or radiologic response was observed.

Conclusions: Our findings support the emerging role of anti-PD-1 immunotherapy in the management of locally advanced periorbital cutaneous squamous cell carcinoma.

Keywords: eye lids; neoplasia; orbit; pathology; treatment medical.

MeSH terms

  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / pathology
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy
  • Retrospective Studies
  • Skin Neoplasms* / etiology

Substances

  • Immune Checkpoint Inhibitors